Literature DB >> 29503197

Local Delivery of miR-21 Stabilizes Fibrous Caps in Vulnerable Atherosclerotic Lesions.

Hong Jin1, Daniel Y Li2, Ekaterina Chernogubova1, Changyan Sun1, Albert Busch2, Suzanne M Eken1, Peter Saliba-Gustafsson1, Hanna Winter1, Greg Winski1, Uwe Raaz3, Isabel N Schellinger3, Nancy Simon1, Renate Hegenloh2, Ljubica Perisic Matic4, Maja Jagodic5, Ewa Ehrenborg1, Jaroslav Pelisek2, Hans-Henning Eckstein2, Ulf Hedin4, Alexandra Backlund1, Lars Maegdefessel6.   

Abstract

miRNAs are potential regulators of carotid artery stenosis and concordant vulnerable atherosclerotic plaques. Hence, we analyzed miRNA expression in laser captured micro-dissected fibrous caps of either ruptured or stable plaques (n = 10 each), discovering that miR-21 was significantly downregulated in unstable lesions. To functionally evaluate miR-21 in plaque vulnerability, miR-21 and miR-21/apolipoprotein-E double-deficient mice (Apoe-/-miR-21-/-) were assessed. miR-21-/- mice lacked sufficient smooth muscle cell proliferation in response to carotid ligation injury. When exposing Apoe-/-miR-21-/- mice to an inducible plaque rupture model, they presented with more atherothrombotic events (93%) compared with miR-21+/+Apoe-/- mice (57%). We discovered that smooth muscle cell fate in experimentally induced advanced lesions is steered via a REST-miR-21-REST feedback signaling pathway. Furthermore, Apoe-/-miR-21-/- mice presented with more pronounced atherosclerotic lesions, greater foam cell formation, and substantially higher levels of arterial macrophage infiltration. Local delivery of a miR-21 mimic using ultrasound-targeted microbubbles into carotid plaques rescued the vulnerable plaque rupture phenotype. In the present study, we identify miR-21 as a key modulator of pathologic processes in advanced atherosclerosis. Targeted, lesion site-specific overexpression of miR-21 can stabilize vulnerable plaques.
Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  atherosclerosis; microRNA; molecular medicine

Mesh:

Substances:

Year:  2018        PMID: 29503197      PMCID: PMC6080193          DOI: 10.1016/j.ymthe.2018.01.011

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  62 in total

1.  MicroRNA-210 Enhances Fibrous Cap Stability in Advanced Atherosclerotic Lesions.

Authors:  Suzanne M Eken; Hong Jin; Ekaterina Chernogubova; Yuhuang Li; Nancy Simon; Changyan Sun; Greg Korzunowicz; Albert Busch; Alexandra Bäcklund; Cecilia Österholm; Anton Razuvaev; Thomas Renné; Hans Henning Eckstein; Jaroslav Pelisek; Per Eriksson; María González Díez; Ljubica Perisic Matic; Isabel N Schellinger; Uwe Raaz; Nicholas J Leeper; Göran K Hansson; Gabrielle Paulsson-Berne; Ulf Hedin; Lars Maegdefessel
Journal:  Circ Res       Date:  2016-11-28       Impact factor: 17.367

2.  Implantation of a carotid cuff for triggering shear-stress induced atherosclerosis in mice.

Authors:  Michael T Kuhlmann; Simon Cuhlmann; Irmgard Hoppe; Rob Krams; Paul C Evans; Gustav J Strijkers; Klaas Nicolay; Sven Hermann; Michael Schäfers
Journal:  J Vis Exp       Date:  2012-01-13       Impact factor: 1.355

Review 3.  MicroRNA Regulation of Atherosclerosis.

Authors:  Mark W Feinberg; Kathryn J Moore
Journal:  Circ Res       Date:  2016-02-19       Impact factor: 17.367

4.  NF-κB targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors.

Authors:  Vivian Y Shin; Hongchuan Jin; Enders K O Ng; Alfred S L Cheng; Wilson W S Chong; Christine Y P Wong; Wai K Leung; Joseph J Y Sung; Kent-Man Chu
Journal:  Carcinogenesis       Date:  2010-11-15       Impact factor: 4.944

5.  REST-miR-21-SOX2 axis maintains pluripotency in E14Tg2a.4 embryonic stem cells.

Authors:  Sanjay K Singh; Anantha Marisetty; Pratheesh Sathyan; Mohamedi Kagalwala; Zhaoyang Zhao; Sadhan Majumder
Journal:  Stem Cell Res       Date:  2015-07-02       Impact factor: 2.020

6.  ATG16L1 Expression in Carotid Atherosclerotic Plaques Is Associated With Plaque Vulnerability.

Authors:  Joëlle Magné; Peter Gustafsson; Hong Jin; Lars Maegdefessel; Kjell Hultenby; Annika Wernerson; Per Eriksson; Anders Franco-Cereceda; Petri T Kovanen; Isabel Gonçalves; Ewa Ehrenborg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-03-12       Impact factor: 8.311

7.  MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts.

Authors:  Thomas Thum; Carina Gross; Jan Fiedler; Thomas Fischer; Stephan Kissler; Markus Bussen; Paolo Galuppo; Steffen Just; Wolfgang Rottbauer; Stefan Frantz; Mirco Castoldi; Jürgen Soutschek; Victor Koteliansky; Andreas Rosenwald; M Albert Basson; Jonathan D Licht; John T R Pena; Sara H Rouhanifard; Martina U Muckenthaler; Thomas Tuschl; Gail R Martin; Johann Bauersachs; Stefan Engelhardt
Journal:  Nature       Date:  2008-11-30       Impact factor: 49.962

8.  RASSF1A inactivation unleashes a tumor suppressor/oncogene cascade with context-dependent consequences on cell cycle progression.

Authors:  Rosalyn R Ram; Saurabh Mendiratta; Brian O Bodemann; Michael J Torres; Ugur Eskiocak; Michael A White
Journal:  Mol Cell Biol       Date:  2014-04-14       Impact factor: 4.272

9.  A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys.

Authors:  Kaveh Hajifathalian; Peter Ueda; Yuan Lu; Mark Woodward; Alireza Ahmadvand; Carlos A Aguilar-Salinas; Fereidoun Azizi; Renata Cifkova; Mariachiara Di Cesare; Louise Eriksen; Farshad Farzadfar; Nayu Ikeda; Davood Khalili; Young-Ho Khang; Vera Lanska; Luz León-Muñoz; Dianna Magliano; Kelias P Msyamboza; Kyungwon Oh; Fernando Rodríguez-Artalejo; Rosalba Rojas-Martinez; Jonathan E Shaw; Gretchen A Stevens; Janne Tolstrup; Bin Zhou; Joshua A Salomon; Majid Ezzati; Goodarz Danaei
Journal:  Lancet Diabetes Endocrinol       Date:  2015-03-26       Impact factor: 32.069

Review 10.  Development of microRNA therapeutics is coming of age.

Authors:  Eva van Rooij; Sakari Kauppinen
Journal:  EMBO Mol Med       Date:  2014-07       Impact factor: 12.137

View more
  32 in total

1.  Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics.

Authors:  Suowen Xu; Danielle Kamato; Peter J Little; Shinichi Nakagawa; Jaroslav Pelisek; Zheng Gen Jin
Journal:  Pharmacol Ther       Date:  2018-11-13       Impact factor: 12.310

Review 2.  HiPS-Cardiac Trilineage Cell Generation and Transplantation: a Novel Therapy for Myocardial Infarction.

Authors:  Ampadu O Jackson; Huifang Tang; Kai Yin
Journal:  J Cardiovasc Transl Res       Date:  2019-05-31       Impact factor: 4.132

Review 3.  Hemodynamics mediated epigenetic regulators in the pathogenesis of vascular diseases.

Authors:  C L Karthika; S Ahalya; N Radhakrishnan; C C Kartha; S Sumi
Journal:  Mol Cell Biochem       Date:  2020-08-25       Impact factor: 3.396

4.  Identification of miR-17, miR-21, miR-27a, miR-106b and miR-222 as endoplasmic reticulum stress-related potential biomarkers in circulation of patients with atherosclerosis.

Authors:  Pelin Telkoparan-Akillilar; Dilek Cevik
Journal:  Mol Biol Rep       Date:  2021-04-15       Impact factor: 2.316

5.  MicroRNA-21 and the Vulnerability of Atherosclerotic Plaques.

Authors:  Temo Barwari; Marieke Rienks; Manuel Mayr
Journal:  Mol Ther       Date:  2018-03-21       Impact factor: 11.454

Review 6.  Regulatory Non-coding RNAs in Atherosclerosis.

Authors:  Andreas Schober; Saffiyeh Saboor Maleki; Maliheh Nazari-Jahantigh
Journal:  Handb Exp Pharmacol       Date:  2022

7.  Reduction of TMAO level enhances the stability of carotid atherosclerotic plaque through promoting macrophage M2 polarization and efferocytosis.

Authors:  Weihao Shi; Yijun Huang; Zhou Yang; Liang Zhu; Bo Yu
Journal:  Biosci Rep       Date:  2021-05-28       Impact factor: 3.840

Review 8.  Non-coding RNAs in cardiovascular cell biology and atherosclerosis.

Authors:  Francesca Fasolo; Karina Di Gregoli; Lars Maegdefessel; Jason L Johnson
Journal:  Cardiovasc Res       Date:  2019-10-01       Impact factor: 10.787

9.  Genomic Strategies Toward Identification of Novel Therapeutic Targets.

Authors:  Thorsten Kessler; Heribert Schunkert
Journal:  Handb Exp Pharmacol       Date:  2022

10.  Chitinase 3 like 1 is a regulator of smooth muscle cell physiology and atherosclerotic lesion stability.

Authors:  Pavlos Tsantilas; Shen Lao; Zhiyuan Wu; Anne Eberhard; Greg Winski; Monika Vaerst; Vivek Nanda; Ying Wang; Yoko Kojima; Jianqin Ye; Alyssa Flores; Kai-Uwe Jarr; Jaroslav Pelisek; Hans-Henning Eckstein; Ljubica Matic; Ulf Hedin; Philip S Tsao; Valentina Paloschi; Lars Maegdefessel; Nicholas J Leeper
Journal:  Cardiovasc Res       Date:  2021-12-17       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.